Rapid PCR Immunoassay Developed for Malaria Diagnosis
|
By LabMedica International staff writers Posted on 29 Aug 2012 |
A polymerase chain reaction (PCR) immunoassay has been developed that detects the different malaria species and differentiates between Plasmodium falciparum and P. vivax.
The test, which combines PCR with a nucleic acid lateral flow immunoassay (PCR-NALFIA) for amplicon detection, was thoroughly evaluated for the analytical sensitivity and specificity in the laboratory, the robustness, and reproducibility in a ring trial and accuracy and predictive value in a field trial.
Investigators at the Royal Tropical Institute (Amsterdam, The Netherlands) developed a PCR-NALFIA and tested its validity by analyzing 241 malaria positive and negative samples from travelers returning from malaria-endemic areas and samples provided by the Dutch blood bank considered negative for malaria. Also tested was a blood sample from Sudanese patients with a confirmed P. falciparum infection. Accuracy was evaluated in Thailand and compared to expert microscopy and rapid diagnostic tests (RDTs). A nitrocellulose membrane of 120 mm (Millipore, Amsterdam, The Netherlands) was used for the preparation of the NALFIA.
The analytical sensitivity and specificity were very high, but were slightly less sensitive for the detection of P. vivax than for P. falciparum. The reproducibility tested in three laboratories was very good, though this evaluation showed that the PCR machine used could influence the results. In the field trial in Thailand, the overall and P. falciparum-specific sensitivity and specificity was good ranging from 0.86-1 and 0.95-0.98 respectively, compared to microscopy. P. vivax detection was better than the sensitivity of RDT, but slightly less than microscopy performed in this study.
The authors concluded that the assay in its current format, or slightly modified with more sensitive detection of P. vivax, could be an excellent tool for epidemiological studies on prevalence or distribution of parasites. In addition, it could be used as a screening tool at regional level for malaria control programs, especially in countries with declining transmission. Molecular tools have been shown to be especially valuable in areas where there is moderate to little transmission and PCR-NALFIA could be a usable simple method in these settings. The study was published on August 17, 2012, in the Malaria Journal.
Related Links:
Royal Tropical Institute
Millipore
The test, which combines PCR with a nucleic acid lateral flow immunoassay (PCR-NALFIA) for amplicon detection, was thoroughly evaluated for the analytical sensitivity and specificity in the laboratory, the robustness, and reproducibility in a ring trial and accuracy and predictive value in a field trial.
Investigators at the Royal Tropical Institute (Amsterdam, The Netherlands) developed a PCR-NALFIA and tested its validity by analyzing 241 malaria positive and negative samples from travelers returning from malaria-endemic areas and samples provided by the Dutch blood bank considered negative for malaria. Also tested was a blood sample from Sudanese patients with a confirmed P. falciparum infection. Accuracy was evaluated in Thailand and compared to expert microscopy and rapid diagnostic tests (RDTs). A nitrocellulose membrane of 120 mm (Millipore, Amsterdam, The Netherlands) was used for the preparation of the NALFIA.
The analytical sensitivity and specificity were very high, but were slightly less sensitive for the detection of P. vivax than for P. falciparum. The reproducibility tested in three laboratories was very good, though this evaluation showed that the PCR machine used could influence the results. In the field trial in Thailand, the overall and P. falciparum-specific sensitivity and specificity was good ranging from 0.86-1 and 0.95-0.98 respectively, compared to microscopy. P. vivax detection was better than the sensitivity of RDT, but slightly less than microscopy performed in this study.
The authors concluded that the assay in its current format, or slightly modified with more sensitive detection of P. vivax, could be an excellent tool for epidemiological studies on prevalence or distribution of parasites. In addition, it could be used as a screening tool at regional level for malaria control programs, especially in countries with declining transmission. Molecular tools have been shown to be especially valuable in areas where there is moderate to little transmission and PCR-NALFIA could be a usable simple method in these settings. The study was published on August 17, 2012, in the Malaria Journal.
Related Links:
Royal Tropical Institute
Millipore
Latest Microbiology News
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








